Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Metformin should remain the first choice for the treatment of type 2 diabetes, even in the face of competition from a host of newer agents, concludes a new review.
Nisa M Maruthur, MD, of Johns Hopkins University School of Medicine, Baltimore, Maryland, led the review, published todayin the Annals of Internal Medicine.
"We conclude that metformin should remain a first-line therapy because its effect on HbA1c is similar to other medications. Metformin has a long-term safety profile, it's weight neutral or helps people lose weight, it has gastrointestinal side effects but they are avoidable or tolerable, and of course metformin looks better for cardiovascular mortality than sulfonylureas," she toldMedscape Medical News in an interview.
http://www.medscape.com/viewarticle/862080
(free registration)
Nisa M Maruthur, MD, of Johns Hopkins University School of Medicine, Baltimore, Maryland, led the review, published todayin the Annals of Internal Medicine.
"We conclude that metformin should remain a first-line therapy because its effect on HbA1c is similar to other medications. Metformin has a long-term safety profile, it's weight neutral or helps people lose weight, it has gastrointestinal side effects but they are avoidable or tolerable, and of course metformin looks better for cardiovascular mortality than sulfonylureas," she toldMedscape Medical News in an interview.
http://www.medscape.com/viewarticle/862080
(free registration)